

Persistent microscopic haematuria in childhood

Rachel Lennon

*Professor of Nephrology & Consultant Paediatric Nephrologist,
Manchester. UK*

Nephrology for the Paediatrician


15th June 2018

Post Graduate Centre, Manchester Royal Infirmary

Causes of haematuria in children


- Glomerular
 - Glomerulonephritis
 - C3 deposition
 - IgA disease (Henoch-Schönlein Purpura)
 - **Basement membrane glomerulopathy**
- Non-glomerular
 - Infection, hypercalciuria, renal stone disease, polycystic kidneys, tumours, arteriovenous malformation, loin-pain-haematuria syndrome, fabricated/induced illness
- 1% general population, 30-50% familial condition

A specialised capillary wall



Lennon R, Randles MJ, Humphries MJ:
The Importance of Podocyte Adhesion for a Healthy Glomerulus. *Frontiers* 2014

Red cell traversing the barrier




Collar JE, Ladva S, Cairns T and Cattell V:
Red cell traverse through thin glomerular basement membranes *Kidney International* 2001

Familial haematuria- genetics

- Alport syndrome
 - *COL4A3,4,5,6*
- Thin basement membrane nephropathy
 - *COL4A3,4*
- Epstein/Fechtner/Sebastian/May-Hegglin
 - Macrothrombocytopenia
 - *MYH9*
- Glomerulopathy with fibronectin deposits
 - *FN1*
- C3/CFHR5 glomerulonephritis
 - *CFHR5*
- More...

Alport Syndrome

- Cecil Alport 1927
- 'Hereditary nephritis', hearing loss, lenticonus
- Rare: 1-5000-1:10000
- 1-2% of ESRD
- Mutations
 - *COL4A3, A4*- autosomal recessive
 - *COL4A5*- X-linked
- Impaired collagen IV assembly
 - kidney, inner ear and eye



Irregular GBM, basket weave, Lamellation

Collagen network required to maintain long term GBM integrity

Heterozygous mutations in *COL4A3/A4*

<http://www.kidney-international.org>


clinical investigation

© 2014 International Society of Nephrology

see commentary on page 1081

Rare hereditary *COL4A3/COL4A4* variants may be mistaken for familial focal segmental glomerulosclerosis

Andrew F. Malone^{1,2}, Paul J. Phelan^{1,2}, Gentzon Hall^{1,2}, Umrhan Cetincelik^{1,2}, Andrea S. Alonso^{1,4}, Ruiji Jiang^{1,4}, Thomas B. Lindsey¹, Guanghong Wang¹, Stephen R. Smith², Nicholas J.A. Webb⁵, Philip A. Kalra⁶, Adebowale O. Ogunbiyi⁷, Peter J. Conlon⁹, J. Charles Jennette¹⁰, David N. Howell¹¹, Michelle P. Winn¹² and Rasheed A. Gbadegesin^{1,4}





Shaw⁸,

- Lifelong surveillance

Intervention

Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy



Oliver Gross *et al* Kidney International 2012

Intervention

- RAAS blockade:
 - ACE inhibition/Angiotensin receptor blockade
 - *Savigne J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 2013;24(3):364-75.*
- Current trials
 - Anti-miR 21: Fibrosis
- Future trials

Summary

- Causes of haematuria
- Microscopic haematuria is **not benign**
- Importance of genetic testing
- Patient registry
- Lifelong surveillance: BP and urinalysis
- Use of RAAS inhibitors for persistent proteinuria